AstraZeneca steps out from Daiichi's shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from AbbVie and Pfizer.